Medronic Acid
drugOn this page
Also known as Acide medroniqueAcido medronicoMedronatePhosphonic acidmethylenebis-methylenedi-Methylene diphsphonatemethylenediphosphonic acidSID3714055BisphosphonateSID144204525Methylene diphosphonic acidmethylenebis(hydrogen phosphonate)MEDRONIC-ACIDMEDRONIC_acid
Summary
Medronic Acid (CHEMBL180570) is a phase-3 clinical-stage small-molecule bone density conservation agent; indicated across 3 conditions including chronic kidney disease and osteogenesis imperfecta.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 12
- Chemistry: 176 Da · CH6O6P2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL180570 |
| Name | Medronic Acid |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 16124 |
| ChEBI | CHEBI:43945 |
| Molecular formula | CH6O6P2 |
| Molecular weight | 176 |
| InChIKey | MBKDYNNUVRNNRF-UHFFFAOYSA-N |
SMILES: C(P(=O)(O)O)P(=O)(O)O
IUPAC name: phosphonomethylphosphonic acid
ChEBI definition: A 1,1-bis(phosphonic acid) consisting of methane substituted by two phosphonic acid groups.
Pharmacological roles (ChEBI): bone density conservation agent, chelator.
Also known as: Acide medronique, Acido medronico, Medronate, Medronic acid, Phosphonic acid, methylenebis-, methylenedi-, Methylene diphsphonate, methylenediphosphonic acid, SID3714055, Bisphosphonate, MEDRONIC ACID
Parent form; salt/anhydrous children: CHEMBL2105165
Patent coverage: 13,143 distinct patent families (33,917 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, Thyroid hormone receptor beta, 72 kDa type IV collagenase, Mitogen-activated protein kinase 1, 3-hydroxyacyl-CoA dehydrogenase type-2.
Bioactivity
ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| KDM4E | 6.45 | Potency | 354.8 | nM | CHEMBL_ACT_3742136 |
| MAPK1 | 5.45 | Potency | 3548 | nM | CHEMBL_ACT_4713727 |
| A8B2U2 | 5.2 | Potency | 6295 | nM | CHEMBL_ACT_4598005 |
| HSD17B10 | 5.2 | Potency | 6310 | nM | CHEMBL_ACT_4869431 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic kidney disease | 3 | MONDO:0005300 | EFO:0003884 |
| osteogenesis imperfecta | 3 | MONDO:0019019 | MONDO:0019019 |
| postmenopausal osteoporosis | 2 | MONDO:0008159 | EFO:0003854 |
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE4 | 4 |
| PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05764733 | PHASE4 | RECRUITING | Bone, Exercise, Alendronate, and Caloric Restriction |
| NCT01882400 | PHASE4 | COMPLETED | Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy |
| NCT03811509 | PHASE4 | UNKNOWN | Breast Cancer Women on Aromatase Inhibitors Treatment |
| NCT04149405 | PHASE4 | COMPLETED | Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis |
| NCT05768854 | PHASE3 | ACTIVE_NOT_RECRUITING | Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta |
| NCT05972551 | PHASE3 | ACTIVE_NOT_RECRUITING | Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta |
| NCT00687661 | PHASE3 | COMPLETED | Queen’s University Investigation of Calcification in Chronic Kidney Disease |
| NCT00306046 | Not specified | COMPLETED | 18F-Fluoride Positron Emission Tomography (PET) in Paget’s Disease of Bone |
| NCT01416194 | Not specified | COMPLETED | Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU) |
| NCT02520362 | Not specified | COMPLETED | Denosumab Safety Assessment in Multiple Observational Databases |
| NCT02731040 | Not specified | COMPLETED | Exome Sequencing for Atypical Femoral Fractures |
| NCT05680194 | Not specified | UNKNOWN | Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: chronic kidney disease, osteogenesis imperfecta